BIIB•benzinga•
Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal
Summary
Biogen and Stoke partner on zorevunersen for Dravet syndrome, with a Phase 3 trial starting in 2025. Stoke gets $165 million upfront and milestone payments.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 18, 2025 by benzinga